Several studies have described dysregulated CD44 expression in the majority of human cancers, including prostate cancer, and until now only few studies have explored the CD44 variants expressed in PCa, providing controversial results, and the functional role of CD44s and CD44v is not fully understood yet. This evidence concerns the gene CD44 and Familial prostate cancer.